An Open-Label Extension Of RPC1063 As Therapy For Moderate To Severe Ulcerative Colitis

Overview

About this study

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Previous participation on a trial of RPC1063 for ulcerative colitis (UC) and may benefit from continued treatment

Exclusion Criteria

  • Require initiation of other therapies used in the treatment of UC
  • Pregnant, lactating, or have a positive serum pregnancy test
  • Have clinically relevant cardiovascular conditions or other relevant disease that would put the patient at risk or make interpretation of the trial difficult

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus JR, M.D.

Closed for enrollment

Contact information:

IBD Clinical Research Unit

(507) 284-5908

More information

Publications

Publications are currently not available